Search

An interview with physician Mark D. Tyson is presented. Tyson discusses the current standard of care for both Bacille Calmette-Guerin (BCG)-naive non-muscle invasive bladder cancer (NMIBC) and BCG-unresponsive high-risk NMIBC, the technology and delivery system behind TAR-200 device, and the SunRise3 study comparing TAR-200 monotherapy induction and maintenance versus TAR-200 plus cetrelimab induction and maintenance versus BCG, and the potential effect of TAR-200 on NMIBC treatment.

The article focuses on a clinical trial investigating the effectiveness of drug gemcitabine/cisplatin plus cemiplimab, with or without fianlimab, in treating bladder cancer. It explains that participants are randomly assigned to receive either the full regimen or a combination without fianlimab, followed by a series of treatments and evaluations, including repeat tumor resections and imaging.

The article reports on a new study by the National Health and Medical Research Council Clinical Trials Centre that explores the efficacy of drug, LSTA1 combined with gemcitabine and nab-paclitaxel in treating pancreatic cancer. Topics discussed include the study's methodology, the results showing a high disease control rate, and the trial's endpoints focusing on progression-free survival and biomarkers.

The article from Lishui People's Hospital provides new research findings on pancreatic cancer. Topics include the role of tumor-derived exosome PPP3CB in inducing gemcitabine resistance in pancreatic cancer cells, the regulatory effect of the miR-298/STAT3 signaling pathway on this resistance, and the use of various assays to analyze the impact of PPP3CB on cell proliferation and apoptosis in gemcitabine-resistant pancreatic cancer cells.

The article focuses on the early termination of the PROOF 301 trial comparing the oral FGFR inhibitor infigratinib to gemcitabine plus cisplatin in treating cholangiocarcinoma. Topics include the preliminary efficacy and safety data of infigratinib, the challenges faced in biomarker-selected studies, and the implications for future confirmatory research in rare tumors.

The article focuses on a new clinical trial (NCT06548412) investigating the addition of CTX-009 to the standard therapy for patients with unresectable or metastatic biliary tract cancers. Topics include the trial's objectives to evaluate safety and efficacy, the combination of CTX-009 with gemcitabine, cisplatin, and durvalumab, and the study's design and recruitment status.

The article offers information on a Phase II study evaluating the combination of pirfenidone with nab-paclitaxel and gemcitabine for metastatic pancreatic cancer. Topics discussed include the overall response rate (ORR) and disease control rate (DCR) achieved with this treatment; the safety profile and incidence of adverse effects; and the impact on CA19-9 levels and patient survival outcomes.

The article from the Second Affiliated Hospital outlines a study on the use of tislelizumab combined with gemcitabine and albumin paclitaxel as preoperative therapy for borderline resectable pancreatic cancer. Topics include the efficacy of the combined therapy in achieving tumor response and resection rates, the safety profile of the treatment with observed adverse events, and the impact on progression-free survival and overall survival rates for patients.

A recent study conducted by researchers at Morgan State University in Baltimore, Maryland, explored the encapsulation of the anticancer drug gemcitabine on a metal-organic framework called porphyrin aluminum. The researchers used a novel technique called mechano-chemistry to encapsulate the drug, resulting in delayed drug release. The study also investigated the cytotoxicity of the encapsulated drug on pancreatic cancer cells. The findings suggest that aluminum metal-organic frameworks could be promising materials for controlled drug release and potential use in drug-eluting implants. [Extracted from the article]

This document provides administrative information about a clinical trial investigating the safety and effectiveness of ivosidenib in combination with durvalumab and gemcitabine/cisplatin as a first-line therapy for participants with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The trial consists of a safety lead-in phase to determine the recommended combination dose, followed by an expansion phase to assess the clinical activity of the treatment. Participants will undergo regular study visits and may receive various tests and examinations. The trial aims to enroll 52 participants and is sponsored by Servier. [Extracted from the article]

A clinical trial, NCT06498648, is currently underway to test the effectiveness and safety of combining the anti-cancer drug abemaciclib with the chemotherapy treatment gemcitabine for patients with soft tissue sarcoma. The trial aims to determine the side effects and optimal dosage of abemaciclib, as well as compare its effectiveness to the standard treatment of gemcitabine with docetaxel. Abemaciclib works by blocking a protein that signals tumor cells to multiply, while gemcitabine blocks DNA production in cells. The trial will assess various outcome measures, including progression-free survival and overall survival. The trial is open to individuals with advanced or metastatic soft tissue sarcoma, leiomyosarcoma, or dedifferentiated liposarcoma, and is expected to be completed by October 1, 2026. [Extracted from the article]

Researchers from the Beckman Research Institute City of Hope have conducted a study on pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of pancreatic cancer. The study focused on the limited effectiveness of gemcitabine-based chemotherapy and the acquisition of chemotherapeutic resistance. The researchers explored the potential of aronia berry extracts (ABEs) to overcome gemcitabine resistance in PDAC cells. Through in vitro experiments and transcriptomic analysis, they identified the MYD88/NF-kB/P-glycoprotein axis as a key pathway contributing to chemoresistance. The combination treatment of ABE and gemcitabine showed significant synergism and anticancer effects, offering a potential adjunctive therapeutic strategy to improve treatment outcomes in PDAC. [Extracted from the article]

A researcher from Ohio University has published new studies and findings on xenografts, specifically in the area of pancreatic cancer. The research focuses on the growth hormone receptor (GHR) and its potential as a therapeutic target. The study found that GHR expression is a negative prognostic factor in patients with pancreatic cancer and that GHR antagonists can significantly improve the efficacy of chemotherapy in mouse xenograft models. The research suggests that targeting GHR could be a promising approach to improving chemotherapeutic outcomes in pancreatic cancer, which is highly resistant to treatment. [Extracted from the article]

A new study conducted at Gifu Municipal Hospital in Japan explores the use of S-IROX as a second-line treatment for unresectable pancreatic cancer after the failure of first-line therapy with Gemcitabine plus nab-paclitaxel. The study used a dose-escalation design and found that the recommended dose of S-IROX was S-1 at 80 mg/m2, oxaliplatin at 85 mg/m2, and irinotecan at 150 mg/m2. The study showed promising results, with a response rate of 33.3% and a disease control rate of 77.8%. Further research is needed to validate these findings. [Extracted from the article]

A patent has been issued for methods of treatment and maintenance therapy for bladder cancer using gemcitabine. Bladder cancer is classified as muscle invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC), and current treatment options are unsatisfactory. The patent describes methods of administering gemcitabine locally to the bladder of an individual during induction and maintenance phases, with rest periods in between. The gemcitabine can be delivered using an intravesicular device, and the maintenance therapy can continue for at least one year. This patent provides potential treatment options for individuals with bladder cancer who are not eligible for or have refused other treatments. [Extracted from the article]

A recent study conducted by researchers at Georgetown University Medical Center explores the use of neoadjuvant treatment in patients with intrahepatic cholangiocarcinoma (ICC). The study focuses on a combination of four drugs - gemcitabine, cisplatin, durvalumab, and tremelimumab - and aims to improve the conversion rate of borderline resectable ICC to resectable ICC. The study is an open-label, single-arm, multicenter phase II trial that will enroll 24 patients and evaluate feasibility, safety, and various endpoints such as overall survival and pathologic complete response. The research suggests that the combination of immunotherapy and chemotherapy may have promising results in treating ICC. [Extracted from the article]

A Phase 2 clinical trial is currently underway to assess the effectiveness and safety of a potential cancer immunotherapy called OBI-833/OBI-821. This treatment combines a carbohydrate-conjugate vaccine with an immune adjuvant and is being tested as maintenance therapy for patients with advanced biliary tract cancer. The trial involves 30 patients who have shown positive responses to initial chemotherapy. The study aims to improve treatment options for this type of cancer by utilizing immunotherapy that targets a specific antigen. The trial is expected to be completed by July 31, 2027. [Extracted from the article]

A study conducted at China Medical University investigated the role and mechanism of S100A9 in gemcitabine resistance in bladder cancer cells. The researchers found that S100A9 is highly expressed in gemcitabine-resistant bladder cancer cells and promotes resistance by targeting the phosphatidylinositol-3kinase/protein kinase B/mammalian target of rapamycin pathway. The findings provide a new therapeutic reference for gemcitabine resistance in bladder cancer cells. The study was funded by the Scientific Research Funding Project of Liaoning Provincial Education Department, Shenyang Science and Technology Plan, and Wu Jieping Medical Foundation. [Extracted from the article]

A new study conducted in Clermont-Ferrand, France compared the cost-effectiveness of gemcitabine plus nab-paclitaxel (GEM-NAB) versus gemcitabine alone (GEM) as second-line treatment for metastatic pancreatic cancer. The study found that patients receiving GEM-NAB had significantly improved overall survival compared to those receiving GEM alone. However, the cost of GEM-NAB was a major consideration, with an incremental cost-effectiveness ratio of 1,449,231 per year of life. The study raises ethical questions about the cost of treatment when no other therapeutic options are available. [Extracted from the article]

A recent study conducted by the HonorHealth Research Institute evaluated the safety, efficacy, and impact on quality of life of a treatment regimen called NABPLAGEM in patients with advanced pancreatic cancer. The study included 42 patients with previously untreated metastatic pancreatic ductal adenocarcinoma. The treatment regimen consisted of nab-paclitaxel, cisplatin, and gemcitabine. The study found that the treatment had efficacy in controlling the disease and improving patient symptoms, but did not achieve the primary objective of a 12-month survival rate. The researchers concluded that NABPLAGEM shows promise for further testing in the neoadjuvant setting. [Extracted from the article]

A recent study conducted at the University of California has investigated the use of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine or gemcitabine for the treatment of advanced solid tumors. The study found that the combination therapy demonstrated acceptable safety and tolerability profiles, with no unexpected toxicities. Encouraging antitumor activity was observed in heavily pre-treated patients, including those with ovarian cancer. The study is ongoing, and further research is being conducted to determine the maximum tolerated dose of the combination therapy. [Extracted from the article]

A recent study conducted at the University of Porto in Portugal explores the potential use of repurposed gemcitabine (GEM) for glioblastoma (GBM) therapy. GEM has shown promise in overcoming drug resistance associated with current treatments for GBM. However, its limited effectiveness is due to its short half-life, high toxicity, and poor permeability across cell membranes. To address these limitations, researchers are investigating drug delivery systems (DDS) such as drug-conjugates and nanoparticles to enhance the therapeutic effect of GEM while reducing off-target toxicity. The study discusses the advantages, limitations, and emerging strategies of these DDS approaches for brain tumor delivery of GEM. The research also examines the preclinical and clinical evidence of GEM efficacy for GBM treatment. [Extracted from the article]

A recent study conducted at University Hospital in Hannover, Germany, has revealed new findings on pancreatic cancer. The research focused on the poor response of pancreatic ductal adenocarcinoma (PDAC) to antineoplastic agents and the discrepancies between preclinical success and clinical failure of compounds in PDAC research. The study investigated the association between the tumor microenvironment (TME) composition and gemcitabine metabolizing enzyme (GME) expression in various in vitro and in vivo models. The results suggest that the expression of GME is independent of the deposition of stromal components, and KPC mice are the most appropriate for studying stromal composition, while PDX mice are best suited for pharmacokinetic studies. [Extracted from the article]

This document provides information about a clinical trial for the drug Adebrelimab in combination with other drugs (Cisplatin and Gemcitabine) for the treatment of biliary tract adenocarcinoma. The trial is not yet recruiting and aims to enroll 80 participants, with an estimated completion date of December 30, 2026. The eligibility criteria include age, confirmed diagnosis, no prior systemic anti-tumor therapy, and adequate organ function. The study is being conducted by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and further contact information is provided for interested individuals. [Extracted from the article]

A new study conducted at the University Hospital Centre Zagreb in Croatia has explored a promising approach to treating non-muscle invasive bladder cancer (NMIBC) in patients who have not received Bacillus Calmette-Guerin (BCG) therapy. The study focused on the use of sequential intravesical administration of gemcitabine and docetaxel (Gem/Doce) as a first-line treatment for high-risk NMIBC. The results showed that Gem/Doce therapy was safe and effective, with high rates of recurrence-free survival and progression-free survival. The researchers recommend further research with extended follow-ups and direct comparisons to other anticancer agents. [Extracted from the article]

Researchers at the Affiliated Hospital of Jiaxing University in China have conducted a study on gemcitabine resistance in pancreatic ductal adenocarcinoma. They found that the expression of Solute carrier 39A1 (SLC39A1) was significantly up-regulated in gemcitabine-resistant samples compared to gemcitabine-sensitive ones. The study also revealed that SLC39A1 promotes gemcitabine resistance by activating AMP-activated protein kinase (AMPK) signaling. These findings suggest that SLC39A1 may be a potential target for overcoming gemcitabine resistance in pancreatic ductal adenocarcinoma patients. [Extracted from the article]

A study conducted at Zhumadian Central Hospital in Henan, China, focused on the design and development of gemcitabine-loaded chitosan-cloaked polymeric nanoparticles for the treatment of glioma cancer. The nanoparticles were found to have improved solubility, stability, and anti-cancer properties compared to pure gemcitabine. The study demonstrated that the newly designed nanoparticles exhibited reduced cytotoxicity and enhanced effectiveness in treating glioma cancer. This research provides valuable insights into the potential of polymeric nanoparticles as a therapeutic approach for gliomas. [Extracted from the article]

This document provides information about a clinical trial for a drug called ProAgio in the treatment of metastatic breast cancer. The trial is not yet recruiting participants and aims to enroll 51 adults with specific characteristics of breast cancer. The trial will assess the safety and efficacy of ProAgio in combination with Gemcitabine. The document also includes administrative information about the trial, such as contact details and collaborators. [Extracted from the article]

A recent study conducted by researchers at Washington University School of Medicine in St. Louis has explored the use of pegylated arginine deiminase (ADI-PEG 20) in combination with gemcitabine and docetaxel for the treatment of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The study found that ADI-PEG 20, when combined with gemcitabine and docetaxel, showed increased expression of hENT, a transporter for gemcitabine, as well as upregulation of dCK to trap gemcitabine inside cancer cells. The phase I portion of the trial is nearing completion, and the phase II portion will evaluate the objective response rate (ORR) in separate cohorts for NSCLC and SCLC. [Extracted from the article]

A study conducted by investigators from the Sarah Cannon Research Institute in Nashville, Tennessee, has found that the combination of durvalumab, gemcitabine, and cisplatin is associated with significant improvements in overall survival for patients with advanced biliary tract cancer. The study analyzed patient-reported outcomes from the TOPAZ-1 trial, which included participants with previously untreated, unresectable, locally advanced, or metastatic biliary tract cancer. The addition of durvalumab did not have a detrimental effect on patient-reported outcomes, suggesting that this treatment regimen is tolerable for patients with advanced biliary tract cancer. The study was supported by AstraZeneca and has been peer-reviewed. [Extracted from the article]

A clinical trial, NCT06457503, is set to begin in August 2024 to investigate the effectiveness of toripalimab in combination with chemotherapy for patients with recurrent metastatic nasopharyngeal cancer. The trial will assess the objective response rate using the Response Evaluation Criteria in Solid Tumors. The study is expected to be completed by December 2027 and is being conducted by Coherus Biosciences, Inc. The trial will involve the intravenous administration of cisplatin, gemcitabine, and toripalimab to eligible participants. [Extracted from the article]

A recent report from Detroit, Michigan discusses the treatment of primary cardiac angiosarcoma, a rare and aggressive form of cancer. The report highlights the case of a 49-year-old man who showed a durable response to gemcitabine monotherapy, a type of chemotherapy. After initial treatment with surgery, adjuvant chemotherapy, and radiation, the patient experienced a recurrence of the cancer with metastases to the liver and bone. However, treatment with gemcitabine and docetaxel followed by gemcitabine monotherapy resulted in no evidence of recurrence for the next three years. This case adds to the limited data available on the management of this rare malignancy and offers hope for patients with this disease. [Extracted from the article]

A study conducted at Sun Yat-sen University Cancer Centre in Guangzhou, China, has found that the combination of toripalimab and chemotherapy shows long-term survival benefits for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). The study followed patients for four years and found that the combination treatment resulted in a 5-year overall survival rate of 52%. Additionally, the study found that monitoring the levels of Epstein-Barr virus (EBV) DNA in patients' blood could be used to predict disease progression and monitor treatment response. The research was published in the Journal of Clinical Oncology. [Extracted from the article]

A clinical trial is currently underway to test the safety and effectiveness of combining gemcitabine and leflunomide in treating advanced unresectable pancreatic cancer. The trial aims to improve the effectiveness of gemcitabine without increasing side effects, potentially leading to better outcomes and quality of life for patients. The trial will evaluate various factors such as survival rates and quality of life for patients receiving the combination treatment. The document also provides information on different medical interventions and procedures, including biospecimen collection, cholestyramine administration, computed tomography (CT) scans, and diagnostic imaging. The trial is currently recruiting participants and is expected to be completed by November 13, 2026, in the United States. [Extracted from the article]

Researchers at Fudan University in Shanghai, China have conducted a study on pancreatic cancer and its resistance to chemotherapy. They found that reprogrammed lipid metabolism contributes to chemoresistance in pancreatic cancer. The study focused on the role of CPT1B, a protein that maintains redox homeostasis and inhibits ferroptosis, in inducing gemcitabine resistance. The researchers concluded that CPT1B may be a promising target for treating patients with gemcitabine-resistant pancreatic cancer. This research has been peer-reviewed and published in the journal Surgery. [Extracted from the article]

A new report from Kyushu University in Beppu, Japan discusses the use of romidepsin as a potential treatment for peripheral T-cell lymphoma (PTCL). The study aimed to determine the safety and efficacy of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin (GDP) therapy. The study included seven patients with relapsed/refractory PTCL, and after a median follow-up of 34 months, the 2-year overall survival rate was 71% and the overall response rate was 57%. Common adverse events included hematological toxicities, but there were no treatment-related mortalities. Further investigation is needed to confirm the safety and effectiveness of this treatment. [Extracted from the article]

Researchers at Yangzhou University in China have published a case report on mucoepidermoid carcinoma (MEC), a rare form of cancer that typically occurs in the salivary glands but can also affect the pancreas. The study focused on a 51-year-old female patient with pancreatic MEC who underwent surgical resection followed by postoperative treatment with paclitaxel and gemcitabine. The treatment successfully halted the spread of metastatic tumors and normalized tumor markers, achieving a Stable Disease status within 6 months. The researchers concluded that gemcitabine and paclitaxel show efficacy in treating pancreatic MEC. [Extracted from the article]

Researchers from Johns Hopkins University have conducted a study on sarcomatoid urothelial cancer of the bladder (SBC), a rare and aggressive subtype of bladder cancer. The study evaluated the clinical activity and safety of neoadjuvant cisplatin plus gemcitabine plus docetaxel (CGD) in muscle-invasive SBC patients. The results showed a pathologic complete response (ypCR) rate of 38% and a < ypT2 rate of 50% in patients who received neoadjuvant CGD. The study also found that SBC tumors have increased expression of immune checkpoint and T-cell genes, which may have therapeutic implications. [Extracted from the article]

A study conducted in Anhui, People's Republic of China, investigated the efficacy of sequential gemcitabine and epirubicin therapy on high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). The study analyzed the records of 100 high-risk NMIBC patients who underwent TURBT at Tongling People's Hospital. The results showed that sequential therapy with gemcitabine and epirubicin was effective in treating high-risk NMIBC after TURBT, reducing postoperative recurrence rates and improving postoperative quality of life without increasing adverse reactions. However, further analysis is needed for improved outcomes. [Extracted from the article]

A study conducted by researchers at the Icahn School of Medicine at Mount Sinai in New York City examined the efficacy of sequential intravesical gemcitabine and docetaxel (Gem/Doce) chemotherapy for non-muscle invasive bladder cancer (NMIBC). The study compared the outcomes of Gem/Doce induction alone versus induction with maintenance, as well as different dosage protocols. The analysis included 83 patients with a median age of 73, and the results showed that Gem/Doce induction with maintenance resulted in significantly better recurrence-free survival (RFS) compared to induction-only. However, further prospective trials are needed to validate these findings. [Extracted from the article]

A recent study conducted by the Eppley Institute for Research in Cancer explores the immunomodulatory functions of the chemotherapy drug gemcitabine in cancer treatment. While immunotherapies have been successful in treating certain cancers, many types of cancer are still unresponsive to immune-based treatments and are primarily managed with chemotherapy drugs. The study highlights gemcitabine's potential as an immune-modifying agent and suggests that it could be used as a priming agent to enhance the efficacy of immunotherapy in traditionally insensitive cancers. The research aims to shed light on gemcitabine's influence on the immune system and its potential for combination therapies. [Extracted from the article]

A recent study conducted by Fudan University in Shanghai, China compared the efficacy and safety of two treatment regimens for patients with advanced pancreatic cancer. The study found that the combination of nab-paclitaxel and S-1 showed slightly improved overall survival and significantly improved overall response rate compared to the gemcitabine plus S-1 regimen. The study also observed benefits in patients with KRAS gene mutations and high C-reactive protein levels. While the study did not meet its primary endpoint, the results suggest meaningful clinical activity and warrant further investigation. [Extracted from the article]

This document provides information about a clinical trial for the treatment of unresectable gallbladder cancer. The trial involves the use of a combination of drugs, including oxaliplatin and gemcitabine, administered intravenously. The study is currently recruiting participants, with an estimated enrollment of 37 patients. The primary completion date for data collection is December 31, 2025. The trial is being conducted in China, and the responsible party is the Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. [Extracted from the article]

A recent study conducted at General University Hospital in Ciudad Real, Spain, explored the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with gemcitabine as a treatment for pancreatic cancer. The researchers hypothesized that this treatment could reduce tumor progression by targeting residual neoplastic volume and pancreatic cancer stem cells. The study involved 42 patients with pancreatic ductal adenocarcinoma, with half receiving HIPEC after surgery and the other half serving as a control group. The results showed that the group receiving HIPEC had lower locoregional recurrence rates and a significant decrease in pancreatic cancer stem cells. This research suggests that HIPEC with gemcitabine may be an effective treatment option for resectable pancreatic ductal adenocarcinoma. [Extracted from the article]

This document provides information on a clinical trial for the treatment of pancreatic cancer. The trial is investigating the use of a drug called onvansertib in combination with gemcitabine and nab-paclitaxel. The trial will evaluate response rates, disease control, and overall survival. [Extracted from the article]